Cohance Lifesciences Reports Q2FY27 Results and Strategic Updates
Cohance Lifesciences Ltd · Financial Result · 06 Nov 2026, 11:29 pm
Cohance Lifesciences Reports Q2FY27 Results and Strategic Updates Cohance Lifesciences reported consolidated Q2FY27 revenue of ₹4,766 million, up 12.9% QoQ but down 14.2% YoY, with adjusted EBITDA margin recovering to 9.6% (from 2.2% in Q1FY27) and adjusted PAT turning positive at ₹74 million. H1FY27 revenue fell 18.6% YoY to ₹8,989 million. Management expects H2 to be materially stronger across revenue and EBITDA. Separately, the board appointed Dr. Kuber Jagdale as CTO & Executive Director for five years from 7th Nov'26 and approved a 26% equity investment (~₹5.72 crore) in a captive solar-wind SPV.
Original exchange filing (PDF)
More announcements from Cohance Lifesciences Ltd
- The Exchange has received the revised disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jasti Property and Equity Holdings .... · 12 Nov 2026
- The Exchange has received the revised disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jasub Property Holdings LLP & Others · 12 Nov 2026
- Investors Meet · 11 Nov 2026
- Transcript of Con call · 11 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jasub Property Holdings LLP & Others · 11 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jasti Property and Equity Holdings Pvt Ltd & Others · 11 Nov 2026
- Investor Presentation · 07 Nov 2026
- Update on USFDA inspection at Pashamylaram Manufacturing facility. · 07 Nov 2026
